"Modeling and Simulation is the love of my heart (other than my families). At Genentech, I dedicate my work to advance the science of modeling and simulation, broaden its impact in drug development, and aim to deliver medicine at the right dose to the right patients."
I joined Genentech in Feb 2009 after working at Eli Lilly in metabolism and neuroscience areas. Genentech has opened a new door for me in oncology, which has always been challenging and exciting at the same time. I started with Modeling and Simulation support for Genentech’s growing small molecule pipeline in oncology at the time, and then gradually took on antibody-drug conjugates (ADCs), mAbs, and afterwards all therapeutic areas. I am currently Global Head of Modeling and Simulation (M&S) in Clinical Pharmacology, and oversee clinical M&S and data programming activities for all molecule types in all Genentech therapeutic areas. I have been actively involved in M&S during development and/or registration for many molecules. My career at Genentech has fulfilled my scientific passion to advance the quantitative science of Modeling and Simulation and broaden its application impact in drug development. More importantly, it also empowers me to help bring novel therapies to patients and potentially improve the life quality for them and their families.
Another thing I am passionate about is active involvement in the scientific community. I have had the privilege of growing both internally and externally since I joined Genentech. I have had the opportunity to serve from contributor to leadership roles in various groups: as member of the Board of Directors since 2014 for International Society of Pharmacometrics (ISoP) and the President for ISoP 2017-2018; conference chair for the 2015 American Conference on Pharmacometrics annual meeting with ~600 attendees; member of the Editorial Board for Clinical Pharmacology and Therapeutics: Pharmacometrics and System Pharmacology (CPT:PSP), and active involvement in various activities for American Society for Clinical Pharmacology and Therapeutics (ASCPT). These activities have brought me valuable learning experiences, and many life-time collaborators and friends.
Biopharm Drug Dispos. 2013 Apr;34(3):141-54.
I devote my career in advancing the science of Modeling and Simulation and as a strong advocator for its application in drug development. My scientific areas of expertise include mechanistic Pharmacokinetics/Pharmacodynamics (PK/PD), Physiologically Based Pharmacokinetics (PBPK), population analysis, trial simulation, disease modeling, literature meta-analysis, and has rich application experience especially in oncology.